Beroni Group ^{Filed, US Offering, Removed, Nasdaq: BRNI}

Beroni Group Limited (“Beroni Group”) is a diversified global biopharmaceutical enterprise with subsidiaries in the US, Australia, China, Hong Kong and Japan. It is currently listed on National Stock Exchange of Australia (“NSX”) under the symbol “BTG” and traded on OTCQX (USA) under the symbol “BNIGF”. The Company has two main business divisions: (1) An innovation pathway comprised of research studies into anti-cancer drugs, cell therapies and detection and treatment of infectious diseases. (2) An e-commerce platform focused on sales of a diverse range of pharmaceutical and healthcare products. We have established international scientific and research collaborations with including renowned universities such as Columbia University in the United States, Nankai University in China, and University of New South Wales (“UNSW”) in Australia. We are currently developing an anti-cancer drug, PENAO, which is expected to enter Phase 2 trials for multiple indications in early 2022. We also expect to initiate Phase 1 trials of our gamma delta T cell candidate for cancer and HIV, and are conducting animal testing on single-domain antibody technology for detecting and treating the COVID-19 virus.